Both are building redundancy into their supply chains to prevent bottlenecks like those that plagued early launches
Novo Nordisks Wegovy pill was approved in late December 2025, marking the first true no-injection GLP-1 era
This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss
The comparison is useful, but it has limits
Clinical trial starting doses The landmark phase 2 trial published in the New England Journal of Medicine randomized 338 participants across multiple dose groups
Theres also dysesthesia, a burning, prickling skin sensation that hit roughly one in eight high-dose patients in the obesity trial and up to one in five in the knee trial, something earlier GLP-1s mostly dont cause